Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Insights into the Phase II WINDOW-2 trial

Michael Wang • 15 Jun 2023
ICML 2023
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies BTK inhibitors Ibrutinib Rituximab Venetoclax
WINDOW-2

In this video, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the results of the Phase II WINDOW-2 trial (NCT03710772). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Wang

3:37
SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCL
Michael Wang • 11 Dec 2023
1:57
Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors
Michael Wang • 6 Sep 2023
1:18
BRUIN study cohort update: pirtobrutinib for patients with MCL
Michael Wang • 6 Sep 2023
2:27
Lisocabtagene maraleucel for R/R MCL: TRANSCEND-NHL-001 update
Michael Wang • 6 Sep 2023

Related Videos

1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
2:45
The value of axi-cel as a second-line treatment in R/R LBCL
Paolo Cortesi • 24 Apr 2024
5:42
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel • 25 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals